歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > CytoskeletalSignaling > BAY1125976

瀏覽歷史

S83126

BAY1125976

源葉(MedMol) ≥98%
  • 英文名:
  • BAY1125976
  • 別名:
  • CAS號:
  • 1402608-02-9
  • 分子式:
  • C23H21N5O
  • 分子量:
  • 383.4457
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S83126-5mg ≥98% ¥1680.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S83126-25mg ≥98% ¥4881.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S83126-100mg ≥98% ¥6179.00元 6 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
  • 靶點: Akt1:5.2 nM (IC50, at 10 μM ATP);Akt2:18 nM (IC50, at 10 μM ATP);Akt3:427 nM (IC50, at 10 μM ATP);Akt
  • 體外研究:
    BAY 1125976 is equally potent against Akt1 (IC50=5.2 nM at 10 μM ATP and 44 nM at 2 mM ATP) and Akt2 (IC50=18 nM at 10 μM ATP and 36 nM at 2 mM ATP) isoforms and up to 86 fold less potent against Akt3 (IC50=427 nM at 10 μM ATP). It inhibits the Akt1 and Akt2 by binding into an allosteric binding pocket formed by kinase and PH domain. It inhibits cell proliferation in a broad panel of human cancer cell lines, particularly in breast and prostate cancer cell lines expressing estrogen or androgen receptors. It effectively blocks Akt signaling by inhibiting the phosphorylation of Akt and the downstream effectors, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), glycogen synthase kinase 3 beta (GSK3s), proline-rich Akt substrate 40 kDa (PRAS40), S6 ribosomal protein (S6RP), and 70 kDa ribosomal protein S6 kinase 1 (70S6K)
  • 體內(nèi)研究:
    BAY 1125976 targets tumors displaying activation of the PI3K/Akt/mTOR pathway. BAY 1125976 exhibits strong in vivo efficacy in both cell line and patient-derived xenograft models such as the KPL4 breast cancer model (PIK3CAH1074R mutant), the MCF7 and HBCx-2 breast cancer models, and the AktE17K mutant driven prostate cancer (LAPC-4) and anal cancer (AXF 984) model
  • 參考文獻(xiàn):
    1. Politz O, et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer. 2017 Jan 15;140(2):449-459.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20°C
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.608 ml 13.04 ml 26.079 ml
    5 mM 0.522 ml 2.608 ml 5.216 ml
    10 mM 0.261 ml 1.304 ml 2.608 ml
    50 mM 0.052 ml 0.261 ml 0.522 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。